Chromium-containing biomimetic cation triaqua-μ3-oxo-μ-hexapropionatotrichromium(III) inhibits colorectal tumor formation in rats

Pickering, Alison; Chang, Christine; Vincent, John B.

doi:10.1016/j.jinorgbio.2004.03.018

Cited by 13 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the current consensus on the essentiality of chromium in the human body is under debate, with some considering it a non-essential element, ongoing research suggests that chromium (III) compound may still manifest potential pharmacological effects [42]. Previous anti-CRC research highlighted that a chromium (III) compound called [Cr 3 O(O 2 CCH 2 CH 3 ) 6 (H 2 O) 3 ] + provides benefits for insulin sensitivity and serum lipids, Am J Cancer Res 2024;14(3):979-995 consequently lowering the risk of CRC in a rat model [18]. Therefore, compounds derived from chromium (III) hold the potential to mitigate the risk of CRC.…”

Section: Discussionmentioning

confidence: 99%

“…In cancer research, the in-situ transition system from chromium (V) to chromium (III) enhanced oxidative stress generation, resulting in efficient cancer therapy in in-vivo and in-vitro settings [17]. A synthesized chromium (III)-containing compound showed potential to decrease the occurrence of colorectal tumors induced by 1,2-dimethylhydrazine in male Sprague-Dawley rats [18]. Due to their potential medical value, the development of novel chromium (III)-based compounds has potential to serve as a therapy for diminishing drug-resistant colon cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel chromium (III)-based compound for inhibition of oxaliplatin-resistant colorectal cancer progression

Chen

2024

Am J Cancer Res

View full text Add to dashboard Cite

Colorectal cancer (CRC) ranks as the third leading cause of cancer-related mortality worldwide. The current standard of care includes systemic chemotherapy with cytotoxic agents, offering palliative relief for severe CRC cases and serving as the primary therapy for metastatic recurrence. However, the development of chemoresistance poses a substantial obstacle in the realm of chemotherapy. This study delved into the potential of a novel chromium (III)-based compound, hexaacetotetraaquadihydroxochromium (III) diiron (III) nitrate, for CRC treatment. The therapeutic promise of this innovative chromium (III)-based compound was explored by utilizing LoVo colon cancer cells and an in-vivo mouse model of CRC. Various dosages of the compound were administered to LoVo parental cells and LoVo oxaliplatin-resistant cells. Findings unveiled that a concentration of 2000 μg/mL of the chromium (III) compound significantly inhibited mesenchymal transition and the migratory and invasive properties of LoVo oxaliplatin-resistant cells. This novel chromium (III)-based compound also demonstrated similar efficacy in other different CRC cell lines. The tumor growth was in the in-vivo mouse model was reduced by this compound. Moreover, the chromium (III)-based compound induced apoptosis by triggering the endoplasmic reticulum (ER) stress pathway in LoVo oxaliplatin-resistant cells. This study illuminates the capacity of the novel chromium (III)-based compound to impede the progression and growth of chemotherapy-resistant CRC. This discovery instills confidence in the potential of this compound as a therapeutic agent for CRC, even in the face of drug resistance. It holds the promise of serving as a valuable asset in the future treatment of chemotherapy-resistant CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Novel chromium (III)-based compound for inhibition of oxaliplatin-resistant colorectal cancer progression

Chen

2024

Am J Cancer Res

View full text Add to dashboard Cite

show abstract

“…Gavage administration of aqueous solutions of the complex (1000 mg Cr/kg body mass, daily for 6 months) resulted in significantly decreased colon tumour incidence. 27 [Cr III (salprn)(H 2 O) 2 ](ClO 4 ), in the presence of sodium azide and upon photoexcitation, causes non-selective cleavage of bovine serum albumin (BSA); EPR evidence suggests the involvement of a chromium(V) species, and fluorescence resonance energy transfer (FRET) measurements from indicate that the chromium(III) complex binds to BSA close to the tryptophan residue. 28 The Schiff base complex [Cr(salen)(H 2 O) 2 ] + was found to have an inhibitory effect on the growth of Shigella dysenteriae; the complex was found to cure the invasive plasmid and thereby render the microbe more sensitive to the tested antibiotics.…”

Section: Introductionmentioning

confidence: 99%